Maintaining a Buy Rating for Precigen Despite Recent Papzimeos Rally

Precigen, Inc. (PGEN) has recently received FDA approval for PAPZIMEOS, a treatment for recurrent respiratory papillomatosis (RRP). Despite a rally, the company remains a buy due to its potential for growth and innovation in the biotechnology sector. The approval of PAPZIMEOS is a significant milestone for Precigen and may lead to increased demand for the treatment. As a result, investors may want to consider maintaining their Buy rating for the company.